

REMARKS

Reconsideration of the above application is respectfully requested.

Claim 62 is pending in the application. Claim 62 has been amended. Entry of this amendment is requested. Upon entry of this amendment, claim 62 is pending. Applicants submit herewith a Request For Extension of Time, which includes the fee for a one-month extension of time.

I. Double Patenting Rejection

The Examiner has rejected claim 62 on the grounds of double patenting over U.S. Patent No 5,739,141. Applicants have included herein a terminal disclaimer. Applicants respectfully request that the Examiner remove his rejection on these grounds.

II. Election

The Examiner has withdrawn part of the subject matter of claim 62 as being directed to the non-elected invention. Applicants have, hereinabove, amended claim 62 accordingly. The amendment finds support in the specification and does not add new matter.

III. Conclusion

It is believed that the above amendments after final rejection are made to place the claim in the condition for allowance. Applicants respectfully request that the Examiner allows claim 62 as amended.

Respectfully submitted,



Elsa Djuardi
Attorney for Applicants
Reg. No. 45,963

Date: August 1, 2003

Agouron Pharmaceuticals Inc./
A Pfizer Company
10777 Science Center Drive
San Diego, CA 92121
Phone: (858) 638-6117
FAX: (858) 678-8233